News
UK to run clinical trial for potential new endometriosis treatment
If successful, the drug could become the first ever non-hormonal and non-surgical treatment for endometriosis

A clinical trial to study a potential new treatment for endometriosis is set to go ahead after researchers in England and Scotland have been awarded nearly £250,000 to investigate a novel drug.
Scientists from the Universities of Edinburgh, Aberdeen and Birmingham will set up and run the clinical trial, called EPIC2, which will involve 100 women with endometriosis in Edinburgh and London.
The study, supported by funding from the women’s health charity Wellbeing of Women and the Scottish Government, will investigate whether a drug called dichloroacetate is an effective pain management treatment for those with the condition.
If successful, the drug could be the first ever non-hormonal and non-surgical treatment for endometriosis and the first new treatment in 40 years.
Endometriosis, a condition that occurs when tissue similar to the lining of the womb grows outside the uterus, affects one and a half million women and those assigned female at birth in the UK.
Earlier research, funded by Wellbeing of Women, discovered that cells from the pelvic wall of women with endometriosis behave differently compared to those without the condition.
Researchers from the University of Edinburgh found that these cells produce higher amounts of lactate, a chemical generated by the body to give us energy when there is a lack of oxygen. This creates an environment that supports the development and growth of endometriosis.
When these endometriosis cells were treated with dichloroacetate, a drug previously used to treat rare metabolic disorders in children, lactate production decreased to normal levels and the size of the endometriosis lesions were reduced.
The EPIC2 research team will build on this knowledge with their clinical trial to determine the optimum dose of dichloroacetate that will provide the most benefit, both in terms of tackling painful endometriosis symptoms and limiting side-effects.
“We’re grateful to Wellbeing of Women and the Scottish Government for giving us the opportunity to progress our research and hopefully move another step closer to the reality of a new, non-hormonal and non-invasive endometriosis treatment,” said Dr Lucy Whitaker, Wellbeing of Women researcher and clinical lecturer in obstetrics and gynaecology at The MRC Centre for Reproductive Health, University of Edinburgh, who is leading the research.
“We know women with endometriosis desperately want more treatment options and better ways to manage the often-debilitating pain that it causes.
“Our research so far shows promising results that dichloroacetate can make a huge difference. I hope our new trial will confirm this and give women hope that new treatments and a better quality of life are on the horizon.”
In the EPIC2 clinical trial, which will start recruiting this autumn, half of the women will receive dichloroacetate while the other half will be given a placebo.
These will be allocated at random and taken for 12 weeks. Every woman will complete a series of questionnaires and give blood samples over the course of two-and-a-half-years.
In a move towards personalised medicine, the dose of dichloroacetate for each woman will be determined by which version of a gene called GSTZ1 they carry.
This gene is responsible for the speed at which dichloroacetate is metabolised by the body.
Some variants do this more slowly than others, which could lead to a build-up of the drug in the bloodstream and increase the risk of side effects unless the dosage is tailored appropriately.
“It is completely unacceptable that there have been no new treatments for endometriosis in 40 years. Too many women and girls are suffering from debilitating symptoms, such as chronic pelvic pain, fatigue and even fertility problems, and current hormonal and surgical treatments aren’t suitable for everyone,” said Janet Lindsay, chief executive of Wellbeing of Women.
“Endometriosis is an extremely under-funded area of women’s health, so we are very pleased to partner with the Scottish Government and invest in medical research that could transform how the condition is treated for millions of women.
“Dichloroacetate has the potential to be the very first non-hormonal and non-invasive treatment for endometriosis, which will be truly ground-breaking. With limited options currently available and no cure, advances like this are long overdue.”
Maree Todd, Women’s Health Minister for Scotland, said:“Scotland is the first country in the UK to introduce a women’s health plan, with endometriosis being one of its early priorities.
“The plan includes several actions to help improve care and support for those with endometriosis, including a vital action to invest in further research to develop much needed improvements into treatment and management options for the condition.
“I am pleased that we are jointly funding research with Wellbeing of Women into what could be the first non-hormonal treatment for endometriosis.
“It is a stepping stone to ensuring that those with endometriosis are given treatment choices that suit their needs.”
Dr Lucky Saraswat, honorary senior lecturer at the University of Aberdeen, added: “Endometriosis can have a significant impact on women’s health and quality of life so I am delighted to be involved in this project which could improve the lives of millions of women.”
“This has a potential to be a real breakthrough in the management of endometriosis. We are very excited to collaborate with Edinburgh University in the EPIC2 trial.”
News
Cultural stigma is a barrier to menopause help, black women say

Cultural stigma and a lack of education are making it harder to get menopause help, ethnic minority women in Jersey have said.
The women came together to share their stories at an event in St Helier hosted by Eve Studios and Liberty Underwear.
Participants were encouraged to speak openly about the symptoms they had experienced.
Angela Mowanga, from Jersey, told ITV Channel: “I became dismissive about signs and symptoms. From our parents and our grandparents, they just carried on.
“I hardly heard the word menopause spoken about in my household. We never had things like hot flushes, itchy skin and tiredness.
“So for us to start talking about menopause, there is a taboo around it. A taboo that comes from ignorance but also not being willing to educate ourselves.
“We as women of colour, societies of colour, we have a lot of taboo subjects, which now have to be highlighted with the generation today.
“However, with the modern day, society is changing. And we hope programmes like this can actually be well received.”
Daisy Ayebale, from Jersey, added: “I think it’s important we are listened to. We need the right information from the experts, but we have also been overlooked when it comes to the healthcare system.
“We need to know this information before it’s too late, before you’re gambling with your health. We are glad to be changing the narrative, we are glad to be changing things right now. We are very hopeful.”
Research shows that black women are more likely to experience menopausal symptoms earlier, more intensely and for longer.
Entrepreneur
TidalSense raises £14m to expand five-minute COPD test across NHS

Cambridge health tech company TidalSense has secured £14.2m in funding led by Cross-Border Impact Ventures to expand its AI-powered lung disease test across the NHS and into Europe and the US.
The investment, which also includes returning backers BGF, Airstream Capital and Foresight Group, will fund the rollout of a handheld diagnostic device that can detect chronic obstructive pulmonary disease (COPD) in as little as five minutes.
It will also support the development of software to diagnose asthma using the same platform.
Donna Parr is managing partner at Cross-Border Impact Ventures.
She said: We look for technology that doesn’t just have a compelling story, but a body of clinical evidence behind it.
“TidalSense has both, with a CEO who has lived the problem she’s solving, and a product that’s already live within the NHS healthcare environment, saving time for patients who have waited years for an answer.
“It is also technology that can improve access to appropriate treatment for COPD sufferers on a global basis and especially for women who are often misdiagnosed.
“This is exactly the kind of impact we want to make with our investments.”
COPD, a progressive condition that restricts airflow and makes breathing increasingly difficult, is the third leading cause of death in England, according to the NHS.
It is responsible for about 30,000 deaths each year and costs the health service an estimated £1.9bn annually.
The company believes its technology could transform how respiratory disease is diagnosed by replacing the need for conventional spirometry in many settings.
Patients simply breathe normally into the handheld device for 75 seconds while artificial intelligence analyses the breath in real time.
A diagnosis is then displayed on screen, allowing clinicians to complete the entire process in around five minutes.
TidalSense says the technology allows clinicians to assess as many as six patients an hour, compared with roughly one an hour using spirometry, which has remained the standard diagnostic test for COPD despite changing little since it was first developed in the 19th century.
Spirometry requires patients to perform forceful breathing manoeuvres and typically needs specialist staff to administer.
TidalSense chief executive Ameera Patel said: “Our ambition is really bold and broad, and it is to have a really significant impact at a population level on chronic respiratory diseases like COPD and asthma.
“We want the test to be available to anyone the first time they present with symptoms, so there’s no bias in accessibility based on where you live, your socio-economic status or your ethnicity.”
Founded in 2013 by chief engineering officer Julian Carter, who holds a PhD in microelectronics and has more than 35 years’ experience developing medical devices, TidalSense has spent more than a decade building the technology.
Its AI models have been trained on more than 2.5 million recorded breaths to identify the distinctive patterns associated with COPD.
The device was introduced into the NHS last year and is now being used by public health providers in Suffolk, north-east Essex, Wales, Glasgow and community lung screening clinics across the south of England.
Pregnancy
Women should not be pressured into an ‘ideal birth’, says health secretary

Women should not feel pressured into an “ideal birth”, health secretary Yvette Cooper has said as she promised major maternity reform.
Cooper has returned to the Department of Health and Social Care 27 years after serving as public health minister under Tony Blair.
She said maternity and child health would be a major focus of her new role, alongside significant reforms to social care.
In an interview with the Guardian, Cooper said the changes should address any pressure on women to pursue a particular birth experience.
Families affected by maternity failures have repeatedly raised concerns that some units were reluctant to escalate medical interventions because of a preference for more natural births.
Cooper said: “I would worry about any mum feeling pressurised that there is somehow a kind of an ideal birth experience to live up to when it’s always different in every case, and you have to follow the evidence, you have to have informed choice.”
As one of her first actions as health secretary, Cooper said she intended to reintroduce binding national maternity standards.
The standards were dismantled during early Conservative NHS reforms and replaced with fragmented arrangements managed separately by individual hospital trusts.
A new maternity taskforce will draft the standards, which will have five central aims.
These include ending regional differences in levels of care and tackling racial inequalities linked to poorer outcomes in deprived areas, particularly for Black and Asian women.
Patient experiences will also form part of how standards are measured, while new targets will aim to identify underperformance before a major scandal develops.
Cooper, who became the first minister to take maternity leave while serving as a junior health minister in the early 2000s, said reports into maternity scandals had been “traumatic” to read and showed that systemic change was needed.
She said: “We’ve always said the NHS is about the cradle to the grave. I want to make it a personal crusade to put the cradle back at the heart of the NHS, and to have much more focus around maternity and child health, the very beginning of a family’s life, making that much more central to the priorities of the NHS, giving it the priority that it really deserves.”
Cooper said discussions about how maternity services could better listen to mothers’ needs had been taking place for the past two decades.
However, she said the emphasis on placing women and families at the centre of care appeared to have been lost.
She said: “It feels incomprehensible that we could be in this situation in the 2020s. I went back to look at some of the things that we’d done 25 years ago.
“And what did strike me was how much we were talking then about women and families being at the centre of care and about listening to women’s views.
“It is really shocking and distressing feeling that has somehow been lost in some of the maternity units where actually it should be the central issue.
“I had a direct interest. I was pregnant at the time. But I am really struck by it now, just feeling like there is this big gap in the priorities that the NHS has been focused on.”
Cooper said she was determined to provide a robust response to Donna Ockenden’s investigations into maternity failures at Shrewsbury and Telford and Nottingham, alongside Baroness Valerie Amos’s national investigation into England’s maternity system.
The investigations highlighted systemic clinical errors, understaffing and toxic institutional cultures. They found that hundreds of infant and maternal deaths were directly linked to failures to listen to mothers and defensive attempts to protect institutions.
Amos’s review faced criticism, including the resignation of an expert adviser over the lack of explicit warnings about “normal birth ideology”.
Families also questioned whether the review’s proposed statutory maternity commissioner would have sufficient independence.
Cooper said she remained committed to introducing the role.
She said: “In the end, the most important people in the maternity services are the mothers, babies, the families. But the point of having a maternity commissioner is to make sure that those issues are championed as part of an NHS.”
She also said reforms needed to address an oppositional culture between doctors and midwives in some trusts over when medical intervention during birth may be necessary.
Cooper said: “The thing that struck me most was the sense of women feeling they weren’t being listened to … And I think that probably does go back to issues around culture.”
Cooper, who served as foreign secretary until recently, said she was prepared for a difficult period in the health role as she sought to implement Andy Burnham’s social care reforms.
She said she remained committed to establishing the national care service announced by the prime minister the previous week.
A longstanding ally of former prime minister Keir Starmer and a former rival of Burnham in the 2015 Labour leadership contest, Cooper said she believed the change of prime minister had been necessary.
She said: “Of course it’s not easy. I really did not think it was possible to win the election when I came back into the shadow cabinet in 2022. It’s only because of what Keir did that we managed to win.
“But we had very difficult local election results … we have to respond to that. But I think we’ve got a sense of energy now.
“All of the things that Andy wants to focus on and drive are also just very much the things that that people are concerned about across the country.”
Entrepreneur1 week agoFertility startup American Baby Company secures US$4m
Entrepreneur2 weeks agoFrom Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation
Insight1 week agoNatural Cycles receives sixth FDA clearance for fertility algorithm
Wellness2 weeks agoAstraZeneca drug approved for breast cancer in EU
Cancer3 days agoCancer patient receives ‘landmark’ treatment in world-first
Sponsored Content2 weeks agoTwo opportunities for women’s health founders closing this autumn
Hormonal health2 weeks agoType 2 diabetes rising among young women, experts warn
Insight1 week agoExperimental treatment significantly slows progression of fatal brain disease in women, study finds












15 Comments